Migraine - Treatment


What is the value of real-world evidence in addressing practical questions related to the use of CGRP pathway mAbs?

While randomised controlled trials (RCTs) have traditionally been the evidentiary standard for determining market authorisations, real-world studies have become increasingly important in providing complementary clinical evidence for several stakeholders, including regulatory and technology assessment authorities.1,2 Read the article below to learn more about the value of real-world e

Login to register to read this article

If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.

Log In

Not registered yet? Register now